Latest Conference Articles

December 2nd 2018, 3:24am

ASH Annual Meeting and Exposition

Treatment with the CD19-targeted CAR T-cell therapy tisagenlecleucel demonstrated sustained rates of relapse-free survival and overall survival at 24 and 18 months for pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia.

December 2nd 2018, 2:28am

ASH Annual Meeting and Exposition

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

November 30th 2018, 9:33am

Ruesch Center Symposium

Five leaders in the fight against gastrointestinal cancers from academia, the community, and clinic were honored at the 2018 Luminary Awards.

November 28th 2018, 2:45am

ASH Annual Meeting and Exposition

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

November 13th 2018, 10:04pm

PER® New York Lung Cancer Symposium

There is limited data on when and whether oncologists should change systemic therapy for patients with non–small cell lung cancer, but some studies provide useful guidance.

November 13th 2018, 7:34pm

PER® New York Lung Cancer Symposium

In light of recent advancements, the current paradigm for choosing first-line therapy for patients with metastatic non–small cell lung cancer who do not harbor an actionable driver oncogene depends upon PD-L1 expression level and histology.

November 13th 2018, 3:26am

PER® New York Lung Cancer Symposium

Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.

November 13th 2018, 1:42am

PER® New York Lung Cancer Symposium

Nasser Hanna, MD, Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research, at Indiana University Melvin and Bren Simon Cancer Center, discusses the efficacy of consolidation immunotherapy in patients with stage III non–small cell lung cancer.

November 12th 2018, 11:00pm

PER® New York Lung Cancer Symposium

Roy S. Herbst, MD, PhD, chief of medical oncology, professor of medicine, Yale Cancer Center, Smilow Cancer Hospital, discusses mechanisms of immune resistance for patients with lung cancer.

November 11th 2018, 2:39am

PER® New York Lung Cancer Symposium

Although driver mutations have been identified for significant NSCLC subsets, patients with metastatic disease benefit from broad panel next-generation sequencing testing because of the growing clinical relevance of less common alterations and gene signatures.

November 11th 2018, 12:40am

PER® New York Lung Cancer Symposium

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the efficiency of next-generation sequencing in lung cancer.

November 11th 2018, 12:02am

PER® New York Lung Cancer Symposium

D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non­–small cell lung cancer.

November 10th 2018, 11:29pm

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the evolving second line of treatment in small cell lung cancer.

November 10th 2018, 2:42am

PER® New York Lung Cancer Symposium

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

November 10th 2018, 2:04am

PER® New York Lung Cancer Symposium

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses optimal treatment regimens for patients with EGFR-positive non–small cell lung cancer.

November 9th 2018, 11:50pm

PER® New York Lung Cancer Symposium

Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.

November 9th 2018, 10:07pm

PER® New York Lung Cancer Symposium

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

November 9th 2018, 8:45pm

PER® New York Lung Cancer Symposium

Alexander E. Drilon, MD, discusses developing markers in the non–small cell lung cancer paradigm.

November 9th 2018, 3:26am

State of the Science Summit on Hematologic Malignancies

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.

November 8th 2018, 12:31am

State of the Science Summit on Hematologic Malignancies

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.